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Abstract Fragile X syndrome (FXS) is the most common
form of inherited intellectual disability (ID). Anxiety and
social withdrawal are considered core features of the FXS
phenotype, yet there is limited diagnostic evidence of the
prevalence of formal anxiety disorders in FXS. This study
assessed the prevalence of anxiety disorders in a sample of 58
males and 39 females with FXS (ages 5.0–33.3 years).
Participants’ parents completed the Anxiety Disorders Inter-
view Schedule (ADIS-IV), a clinical interview based on
DSM-IVcriteria,andtheAnxietyDepressionandMoodScale
(ADAMS), a psychiatric disorders screening instrument
normed in ID. We conducted cognitive (IQ) and autism
(AUT) assessments and surveyed medication use. Despite a
high rate of psychopharmacological treatment, 86.2% of
males and 76.9% of females met criteria for an anxiety
disorder, with social phobia and specific phobia the most
commonly diagnosed. Proband status, gender, and IQ were
not significantly related to any anxiety disorders, however
significantly higher rates of a few anxiety disorders were
found in older age and AUT groups. Significant correlations
betweenADISdiagnosesandADAMSscoresprovidedcross-
validation of instruments, indicating that the ADIS is suitable
foruseinFXS.Agreaterpercentageofoursamplemetcriteria
for most anxiety disorders than has been reported in other ID
groups or the general population. The rate of anxiety
compared to general ID suggests that the FMR1 full mutation
confers an especially high risk for these disorders, regardless
of factors commonly associated with FXS clinical involve-
ment. A thorough clinical assessment and treatment of
anxiety should be included in the FXS standard of care.
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Abbreviations
FXS Fragile X syndrome
FMR1 Fragile X mental retardation 1 gene
FMRP Fragile X mental retardation protein
ID Intellectual disability
DD Developmental delay
ASD Autism spectrum disorder
AUT Autism
SM Selective mutism
WS Williams syndrome
ADIS Anxiety Disorders Interview Schedule
ADAMS Anxiety Depression and Mood Scale
DS Down syndrome
Introduction
Fragile X syndrome (FXS) is the leading cause of genetically
inherited intellectual disability (ID). FXS results from an
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DOI 10.1007/s11689-010-9067-yexpansion of CGG repeats at Xq27.3 in the fragile X mental
retardation gene (FMR1) on the long arm of the X
chromosome. The frequency of the full mutation allele is
approximately one in 2,500 (Hagerman 2008) although the
affected prevalence has been estimated to be one in 3,600
(Crawford et al. 2002; Fernandez-Carvajal et al. 2009)
because some individuals with the full mutation, such as
females, do not have significant ID. The expansion leads to a
reduction or elimination of FMR1 protein (FMRP) production
known to be essential for normal brain function and growth
(Bassell and Warren 2008). Due to the presence of a second
X chromosome, females can be less cognitively impaired
than males but are vulnerable to behavioral and emotional
problems (Lachiewicz 1992, 1995; Lachiewicz and Dawson
1994), as well as math deficits (Murphy 2009; Lachiewicz et
al. 2006). Variability in functioning of the FMR1 gene (X-
activation ratio in females, FMRP expression, methylation,
etc.) leads to heterogeneity in clinical presentation, among
both males and females with FXS (Loesch et al. 2004).
The behavioral phenotype of FXS is characterized by
mild to severe ID, anxiety, social deficits, hyperarousal,
abnormalities in communication, abnormal sensory reactiv-
ity, gaze aversion, inattention, impulsivity, aggression, and
hyperactivity (Sudhalter et al. 1990; Cohen et al. 1991;
Reiss and Freund 1992; Hessl et al. 2001). Anxiety has
been recognized as a prominent feature of FXS, yet the
severity and pervasiveness of clinical anxiety disorders in
this population have not been studied. Despite the lack of
diagnostic information, anxiety symptoms are frequently
treated with medications (Berry-Kravis and Potanos 2004).
In the general population, anxiety disorders are among the
most common psychiatric disorders, occurring in 2.4% to
1 0 . 7 %o fc h i l d r e n( F e r g u s s o ne ta l .1993; McGee et al. 1990;
Costello et al. 2003). As part of an epidemiological study, the
National Institutes of Mental Health (NIMH) developed a
DSM-III-R criteria-based interview (the Diagnostic Interview
Schedule for Children, DISC) to assess the presence of
psychiatric disorders and found that 9.8% of children met
criteria for an anxiety disorder (N=1,289, 9–17 years)
(Shaffer et al. 1996). The most common anxiety disorder
was social phobia, followed by overanxious disorder (anal-
ogous to generalized anxiety disorder in the DSM-IV) and
separation anxiety (4.5%, 3.1%, and 2.3%, respectively). In a
national survey of households (N=9,282), the National
Comorbidity Survey (NCS-R) found that the median age of
onset for anxiety disorders was 11 years, with half of all cases
occurring between 6 and 21 years old (Kessler et al. 2005).
Many studies have reported that girls are at higher risk for an
anxiety disorder, at any age, compared with males (Fergusson
et al. 1993; McGee et al. 1990; Costello et al. 2003).
The clinical assessment of anxiety in individuals with ID,
including those with FXS, can be particularly difficult.
Though psychiatric problems in ID are common, they are
not often accurately identified (Reiss and Valenti-Hein 1994).
Clinical diagnosis of psychiatric problems often relies upon
verbal expression and a degree of personal insight, which
can be lacking in ID. Many treatments, interventions, and
allocation of services are tied to the clinical diagnosis of
these disorders. Therefore, individuals with ID who are not
properly diagnosed may not receive the supports and
treatment they need. The most recent version of the DSM
suggests that adaptations to diagnostic criteria made for
children are appropriate for individuals with ID.
Despite the complexity of psychiatric diagnosis among
those with ID, the risk for psychopathology in this population
is high. It is estimated that individuals with ID are two to four
times more likely than the general population to experience
psychiatric problems (Eaton and Menolascino 1982). Dekker
and Koot (2003) found that 38.6% of individuals with
idiopathic ID met criteria for a psychiatric disorder.
Similar to the general population, anxiety disorders are
prevalent among individuals with ID. Using the DISC to
measure DSM-IV disorders (N=474, ages 7–20 years),
Dekker and Koot (2003) reported anxiety disorders in
21.9% of children with ID. Specific phobia was the most
common (17.5%), followed by obsessive–compulsive dis-
order (OCD; 2.7%) and social phobia (2.5%). Neither
generalized anxiety disorder (GAD) or posttraumatic stress
disorder (PTSD) was found in the sample. In contrast to
general population data, there was no relationship between
age and anxiety disorders, except for OCD. Myers and
Pueschel (1991) found that 22.1% of individuals with
Down syndrome (DS) met DSM-III criteria for a psychiat-
ric disorder. However, anxiety disorders were not common
in those with DS: only 1% of participants were diagnosed
with phobias and 0.8% with OCD.
Other genetically caused neurodevelopmental disorders,
such as Williams syndrome and 22q deletion syndromes,
exhibit higher rates of anxiety compared to the general
population. Previous studies of 22q deletion syndromes have
reportedratesofanxietydisordersrangingfrom32%to60.7%
(Dekker and Koot 2003; Myers and Pueschel 1991; Gothelf
et al. 2007; Prasad et al. 2008). The most common diagnoses
were OCD, specific phobia, and social phobia (32.6%,
32.6%, and 18.6%, respectively). Multiple studies have
described the behavioral and emotional characteristics of
individuals with WS (Einfeld et al. 2001;D y k e n s2003;
Gosch and Pankau 1997). Both WS and FXS share the
features of cognitive deficits and anxiety. While social
withdrawal is associated with FXS, the WS phenotype is
described as extremely social and outgoing. In studies using
a DSM-IV-based interview (Leyfer et al. 2006a, b), 62.1% of
individuals with WS were diagnosed with at least one
anxiety disorder, with specific phobia being the most
common (56.1%) and social phobia occurring in only 2.3%
of the sample. Taken together, these studies show that rates
58 J Neurodevelop Disord (2011) 3:57–67and types of anxiety disorders vary among genetic disorders
causing ID. However, anxiety is more prevalent in these
genetic conditions compared to the general population.
Anxiety symptoms have long been recognized as a
prominent component of the FXS phenotype. In a recent
national survey of 1,492 children with FXS, parents
reported that 70% of males and 56% of females with FXS
had been treated for anxiety symptoms or received a formal
anxiety diagnosis (Bailey et al. 2008). A review of the
literature in FXS shows reliance upon questionnaires and
behavior checklists, many of which were not developed for
use in individuals with ID. Anxiety and social withdrawal
symptoms are commonly reported in parent-report ques-
tionnaire studies of children with FXS.
Lachiewicz (1992) used a parent-report questionnaire,
the Child Behavior Checklist (CBCL), in a sample of 38
females (ages 4–11 years) with FXS. Almost half (47%) of
the girls scored above the 98th percentile on the social
withdrawal subscale. More girls with average IQ (64%)
than those with borderline IQ (28%) or IQs below 70 (46%)
scored above the 98th percentile. This pattern could have
been due to an artifact of the measure since the CBCL
version used had not been developed or normed in ID.
Similar findings were reported using the Conners Rating
Scale to compare a group of females with FXS and a group
of females with developmental delay (DD) without FXS.
There was a significant difference between the percentage
of girls with t-scores above the 98th percentile in the DD
(2%) and FXS (23%) groups (Lachiewicz and Dawson
1994). Similar to the CBCL findings, more girls with FXS
who had normal or borderline IQ had t-scores above the
98th percentile compared to those with IQ scores below 70.
A few studies have used diagnostic criteria to measure
psychiatric problems in FXS. For example, Freund et al.
(1993) assessed a group of FXS females (N=17) and non-
FXS age-matched controls (N=17) (ages 4–27 years old) for
the presence of DSM-III-R psychiatric disorders. Using the
DICA-P interview, there was a greater frequency of avoidant
disorder (11 of 17) and mood disorders (8 of 17) in the FXS
group compared to controls. Two of the 17 females with
FXS met criteria for overanxious disorder, compared to none
of the controls. Further, parents and teachers rated the FXS
group as significantly more withdrawn and depressed
compared to control participants. It is noteworthy that this
study used a behavior checklist normed in both learning
disability and DD populations, as well as a semi-structured
interview and found no association between IQ and anxiety,
as reported in the Lachiewicz studies.
The goal of the present study was twofold. First, we
sought to measure the prevalence and characterize the types
of anxiety problems in individuals with FXS using a
diagnostic clinical interview and questionnaire normed in
ID, while addressing adjustments in the diagnostic formu-
lation related to children and ID. Second, we examined
factors that may be associated with the presence of anxiety
disorders in individuals with FXS. Third, we compared
rates of anxiety disorders in FXS to those reported in the
general population, in ID, and in another specific genetic
syndrome manifesting anxiety, Williams syndrome.
Method
Participants
Participants were 58 males (ages 5.0–26.7 years, M=13.07,
SD=5.60) and 39 females (ages 5.5–33.3 years, M=12.35,
SD=6.17) with a confirmed diagnosis of FXS (see Table 1).
The majority of participants were the first to be identified
with FXS in their family: 64.9% were probands (52 males,
11 females). The remainder of the sample was identified by
cascade DNA testing. Race and ethnicity data were
collected in accordance with NIMH funded project require-
ments. The majority of the sample was Caucasian (78.4%)
and not Hispanic or Latino (64.9%).
Measures
The Anxiety Disorders Interview Schedule for DSM-IV:
Parent Report Version (ADIS-IV) (Silverman and Albano
2004) was administered to measure the presence and severity
of current anxiety disorders according to DSM-IV criteria.
Table 1 Description of participants
Males Females Total
Total N 58 39 97
Age M 13.07 12.35 12.78
SD 5.60 6.17 5.81
Range 5.00–26.71 5.50–33.30 5.00–33.30
IQ M 60.45 77.20 67.18
SD 15.36 20.65 19.41
Range 30–117 40–116 30–117
ID
a status N (%)
ID (FSIQ<70) 45 (77.6) 13 (33.3) 58 (59.8)
Non-ID 12 (20.7) 26 (66.7) 38 (39.2)
ASD
b diagnosis N (%)
No ASD 21 (36.2) 28 (71.8) 49 (50.5)
ASD 10 (17.2) 10 (25.6) 20 (20.0)
Autism 27 (46.6) 1 (2.6) 28 (28.9)
Proband status N (%)
Proband 52 (89.7) 11 (28.2) 63 (64.9)
Non-proband 6 (10.3) 28 (71.8) 34 (35.1)
aID Intellectual Disability,
aASD Autism Spectrum Disorder
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diagnose a variety of anxiety disorders and allows the rater
(the parent) to make dimensional ratings of disorder features.
These ratings indicate either the degree of distress or
interference the item presents in a person’sf u n c t i o n i n g
(0=none to 8=very severe). The test-retest reliability is good
(k=0.73) (Silverman et al. 2001). Inter-rater reliability
between the parent- and child- report versions of the ADIS
forbothprincipaldiagnosisandindividualanxietydisordersis
excellent (k=.80–1.0) (Lyneham et al. 2007). Administration
of the ADIS takes an average of two hours and was
completed with the participant’s mother (89.2%), father
(5.4%) or mother and father combined (5.4%). The ADIS
has been used extensively in published studies of anxiety
across many settings and populations (Ross et al. 2007;
Panichelli-Mindel et al. 2005; Leyfer et al. 2009;B o d d e ne t
al. 2008; Waters et al. 2008), in validation studies (Thaler et
al. 2010; Simon and Bogels 2009; Bodden et al. 2009;
Leyfer et al. 2006b), as well as a federally-funded pediatric
anxiety treatment trial (Compton et al. 2010).
The Anxiety Depression and Mood Scale (ADAMS)
(Esbensen et al. 2003) is a 28-item questionnaire used to
screen for psychiatric disorders in persons with ID.
Behaviors are rated on a 4-point Likert scale ranging from
0( “not a problem”)t o3( “severe problem”). The ADAMS
yields 5 subscale scores: General Anxiety, Social Avoid-
ance, Depression, Manic/Hyperactive and Obsessive/Com-
pulsive Behavior. It was psychometrically evaluated and
normed using 265 individuals and validated with 129
psychiatric patients with ID (Esbensen et al. 2003). For
the current study, the ADIS and ADAMS were completed
by the same respondent (mother or father) within a
maximum interval of 14 days.
Intelligence testing was conducted as developmentally
appropriatebyatrainedclinician.Duetothewideagerangeof
participants,measuresincludedtestsfromtheWechslerScales
of Intelligence: WASI (48.4%), WPPSI-III (8.6%), WAIS-III
(9.7%), WISC-III or WISC-IV (16.1%) and a limited number
of non-verbal intelligence tests (4.3%). Those with an IQ
score below 70 were classified as having an ID.
Assessment for the presence of an autism spectrum
disorder (ASD) included the Autism Diagnostic Observa-
tion Scale (ADOS-G), the Autism Diagnostic Interview—
Revised (ADI-R), DSM-IV criteria and clinical team
consensus as previously described (Harris et al. 2008). All
diagnostic assessments used to determine ASD status were
administered by a trained clinician.
Procedures
Consent or assent was obtained from all participants (and
parents, if applicable) in the study and all procedures were
approved by the institutional review board. Participants
were seen for 1 to 3 days as part of a larger study of the
physiological correlates of anxiety in FXS. A list of current
medications was reported by the parents. The ADIS was
administered by an experienced, licensed clinical psychol-
ogist (D.H.) or graduate level student (L.C.) who had
passed reliability training on the instrument. Training for
the ADIS began with reviewing the interview, observing
both videotaped and live administrations of the interview
and assigning diagnoses and severity ratings for each
interview. Once trainees had obtained three or more
matches on diagnosis and severity, a practice ADIS was
administered and videotaped. The videotape was reviewed
by a licensed clinical psychologist. Once the trainee and the
clinical psychologist matched on diagnoses and severity,
the interviewer was permitted to administer the ADIS for
the study. Disagreements of diagnosis were resolved by
case discussion, with final diagnosis made by the licensed
clinical psychologist. One-third of all cases were reviewed
as a team.
During the ADIS interview, specific examples were
requested of the parent to check for comprehension and
ensure proper symptom endorsement. For example, if
fear of dogs was endorsed in the specific phobia section,
parents were asked to describe the reaction, the last time
it occurred, the consistency of the fear, and the degree
and type of interference in daily functioning. Parents
were also asked whether their child ‘reported’ fear or if
they had ‘observed’ a reaction or behavior demonstrating
fearfulness or distress. The collection of this information
allowed for any necessary diagnostic adjustments, as
described below.
The information collected during the ADIS interview
along with the age, ID classification and autism status of
each individual were used to make diagnostic determina-
tions. The DSM-IV-TR notes that in children and adults
with ID who function at similar levels, adaptations for
children are applicable. As such, in children with or without
ID and adults with ID, DSM-IV adaptations for children
were followed. For example, specific phobia in children
may be expressed as crying, tantrums, freezing or clinging.
Further, children may not recognize that the fear is
excessive or unreasonable. Standard DSM-IV criteria were
used in adults without ID.
Statistical analysis
Possible factors related to anxiety
Exploratory analyses of the relationships between proband
status, autism status, IQ score, ID status, gender and age
with both the presence and number of anxiety disorders
were conducted in preparation for planned multiple logistic
(MLR) and multiple linear (MRA) regressions, respectively.
60 J Neurodevelop Disord (2011) 3:57–67Due to a lack of significant relationships in the exploratory
analyses, multiple univariate comparisons and a high rate of
anxiety disorders in this sample, MLR and MRA were
ultimately not conducted.
Cross-validation of interview and questionnaire data
Spearman’s rho correlations were used to assess the associa-
tion between each anxiety disorder and each ADAMS
subscale. Pearson’s moment correlations were used to assess
the relationship between total number of anxiety disorders
diagnosed and ADAMS scores. These relationships were
examined to validate the use of the ADIS in FXS.
Comparison of anxiety disorder rates
Proportion tests (z-tests) (Newcombe 1998a, b)w e r e
carried out using the SPSS (v17) Custom Tables module
(SPSS Statistics 2007a, b) to determine if the prevalence of
anxiety disorders in the current study were significantly
different from prevalence in previous studies among the
following groups: general population, idiopathic ID, and
Williams syndrome. Alpha values were adjusted for
multiple comparisons using a Bonferroni correction.
Results
Anxiety
Among the entire sample of participants with FXS, 82.5% met
criteria for at least one anxiety disorder and 58.3% met criteria
for multiple anxiety disorders (see Table 2). The majority of
participants met criteria for one to three of the nine anxiety
disorders assessed. The most common anxiety disorders were
specific phobia (64.9% of males and 51.4% of females), social
phobia (34.5% of males and 39.5% of females) and SM
(28.1% of males and 25.3% of females). Many more
participants had clinical symptoms of anxiety, although they
did not meet full diagnostic criteria for the disorder. This
demonstrated a range of clinical involvement related to
anxiety, among both males and females with FXS (see Figs. 1
and 2, respectively).
For social phobia only, an additional diagnostic category
was examined based on the authors’ determination that the
screeningquestion(“Insocialsituations,doesyourchildworry
thatthey might do something that will be embarrassing?”)w a s
beyond the cognitive or expressive language capacity of most
of those with ID. This modification to the criteria and resulting
category is hereafter termed “social phobia (adjusted)”.
Elimination ofthe screeningquestioncriteria (but maintenance
ofallothercriteria)increasedtherateofsocialphobiato60.3%
of males and 55.3% of females. This adjustment also resulted
in an increased rate of social phobia among participants with
ID (from 32.8% to 69.0%). This single modification allowed
for a diagnosis of social phobia in individuals who demon-
strated clinically significant impairment as a result of social
phobia symptoms, but who are not able to verbalize or explain
“a worry that they might do something embarrassing.”
Use of medications
Medications were used by 53.6% of participants. The most
common class of medication was selective serotonin reuptake
inhibitors (SSRIs), used by 27.8% of participants (24.1% of
males and 33.3% of females). Stimulants and atypical
Table 2 Percentage of individuals with FXS meeting criteria for DSM-IV anxiety disorders
Gender Autism status ID status
Anxiety type Total Female Male No autism ASD
a Autism Non- ID
b ID
b
Multiple disorders 58.3% 55.3% 60.3% 56.3% 55.0% 64.3% 51.4% 63.8%
Any disorder 82.5% 76.9% 86.2% 81.6% 85.0% 82.1% 76.3% 87.9%
Separation anxiety 11.5% 18.4% 6.9% 14.6% 10.0% 7.1% 13.5% 10.3%
Social phobia 36.5% 39.5% 34.5% 39.6% 30.0% 35.7% 43.2% 32.8%
Social phobia (adj.) 58.3% 55.3% 60.3% 58.3% 45.0% 67.9% 43.2% 69.0%
Specific phobia 59.6% 51.4% 64.9% 50.0% 65.0% 71.4% 42.9% 70.7%
Panic disorder 5.4% 2.7% 7.1% 6.4% .0% 7.1% 2.8% 6.9%
Agoraphobia 12.9% 10.8% 14.3% 11.1% 5.0% 21.4% 5.6% 17.9%
GAD 23.7% 18.4% 27.3% 30.4% 15.8% 17.9% 27.8% 21.4%
OCD 23.7% 18.4% 27.3% 26.1% 20.0% 22.2% 19.4% 26.8%
PTSD 4.3% 5.4% 3.5% 6.5% .0% 3.6% 8.6% 1.7%
Selective mutism 25.3% 21.1% 28.1% 17.0% 25.0% 39.3% 21.1% 27.6%
aASD Autism Spectrum Disorder,
bID Intellectual Disability
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respectively). A greater percentage of probands (27.0%) than
non-probands (8.8%) were using anti-psychotics. A similar
pattern was found for the use of anti-psychotics among those
with (27.6%) and without ID (10.7%). Among the subset of
participants taking medications, more females (72.2%) were
taking an SSRI than males (41.2%). A more detailed
description of medication usage is in Table 3.
Possible factors related to anxiety
The relationships between proband status and gender with
the presence of any or total number of anxiety disorders
were not significant (p=.07 and p=.18, respectively).
Social phobia and PTSD were significantly more common
in individuals over age 18 than among children (p<.05). A
greater percentage of participants with ID met criteria for
all anxiety disorders measured, except for Separation
Anxiety, Social Phobia (unadjusted), GAD and PTSD.
Comparison of FXS+ID and FXS-ID groups revealed a
higher rate of specific phobia and social phobia (adjusted)
among those with a below average IQ (p<.05). Note that
there was not a significant difference in the rate of social
phobia among FXS+ID and FXS-ID when the aforemen-
tioned adjustment to criteria was not made. The percentage
of participants who met criteria for an anxiety disorder
Fig. 2 DSM-IV anxiety disorders: females with fragile X syndrome. Features (open portion of bars) shows the percentage of participants who
demonstrated clinically significant symptoms but did not meet formal diagnostic criteria
Fig. 1 DSM-IV anxiety disorders: males with fragile X syndrome. Features (open portion of bars) shows the percentage of participants who
demonstrated clinically significant symptoms but did not meet formal diagnostic criteria
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Some anxiety disorders, such as Specific Phobia and Social
Phobia (adjusted), occurred more frequently among partic-
ipants with Autism. Significantly more participants with an
ASD were diagnosed with SM (p<.05), despite accounting
for communication deficits among those with an ASD.
Cross-validation of interview and questionnaire data
The ADAMS Social Avoidance subscale was significantly
correlated with two social anxiety disorders: Social Phobia
(rho=.263,p=.02)andSelectiveMutism(rho=.421,p=.001).
The ADAMS OCD subscale was significantly correlated with
an ADIS OCD diagnosis (rho=.252, p=.04). The ADAMS
General Anxiety subscale was significantly correlated with
many ADIS diagnoses (rho=.251 to .338, p<.05) and total
number of ADIS anxiety diagnoses (r=.508, p<.001). No
significant relationships were found between the ADAMS
Depression subscale and the presence of any ADIS diagnosis.
Comparison of anxiety in FXS with other groups
Prevalence rates of anxiety disorders were compared to the
rates in a group with idiopathic ID, the general population,
and a group of individuals with Williams syndrome (WS)
(see Table 4). The comparison of FXS+ID to idiopathic ID
included data from the largest (N=474) epidemiological
study of psychiatric disorders among children (ages
6–18 years) with idiopathic ID using DSM-IV criteria
(Dekker and Koot 2003). The comparison of FXS-ID to the
general population was based on the findings from the
largest published NIMH epidemiological study of psychi-
atric disorders in children and adolescents (N=1,285, ages
9–17 years) using DSM-III-R criteria (Shaffer et al. 1996).
Finally, the entire sample of FXS was compared to a sample
of children (N=132, ages 4–17 years) with WS assessed
with the ADIS who had a similar range of cognitive ability
(Leyfer et al. 2009).
More individuals with FXS+ID met criteria for an
anxiety disorder than has been reported in other idiopathic
ID groups (see Table 4). Rates of seven of the ten anxiety
disorders included in the comparison were significantly
higher in the FXS+ID group than the idiopathic ID group.
In both the idiopathic ID and FXS+ID groups, specific and
social phobias were the most commonly diagnosed anxiety
disorders.
More than three-quarters of the FXS group with an
average or borderline IQ (FSIQ>70) met criteria for at least
one anxiety disorder, compared to just 9.8% of the general
population. The rates of all anxiety disorders in the FXS-ID
group were significantly higher compared to the general
population, with the exception of separation anxiety.
In comparison to a sample of individuals with WS with a
similar level and range of cognitive abilities, the rate of
specific phobia was similar. The rates of specific phobia,
separation anxiety and PTSD were not significantly
different between the FXS and WS groups. The number
of individuals in the FXS group who met criteria for at least
one anxiety disorder was significantly higher than the group
with WS. Though the rate of GAD in WS was more than
double the rate in the general population, it remained
significantly lower compared to FXS. As expected, the rate
of social phobia in FXS was much higher than in WS or ID.
Discussion
This study documented high rates of anxiety disorders in a
large sample of individuals with FXS, using appropriate
clinical diagnostic criteria for those with or without ID.
Though the severity of anxiety and social withdrawal
behaviors in FXS have been well described via parent-
report behavior checklists, this is the first study to use a
clinical tool for the assessment of DSM-IV diagnoses,
among both males and females and across cognitive
abilities. This study found similar results between a
questionnaire previously developed and validated for use
in ID and a semi-structured interview based on DSM-IV
criteria, supporting both the appropriateness of the DSM-IV
based interview used, as well as the specificity of both
measures. The pervasiveness of anxiety in this population
suggests a profound effect of the FMR1 gene mutation on
anxiety symptoms.
The high percentage of females with FXS who met
criteria for an anxiety disorder is in contrast to previous
research. A study using a semi-structured diagnostic
interview (SADS-L) to compare emotional problems in
Table 3 Medication use among males & females with FXS
Total Gender
Medication type Female Male
SSRI 27.8% 33.3% 24.1%
Anti-depressant 6.2% 2.6% 8.6%
Anti-psychotic 20.6% 15.4% 24.1%
Stimulant 24.7% 17.9% 29.3%
AED/Anti-convulsant 7.2% .0% 12.1%
SNRI 4.1% 2.6% 5.2%
Miscellaneous 18.6% 15.4% 20.7%
Sedative 1.0% .0% 1.7%
Anti-histamine 1.0% .0% 1.7%
Anti-anxiety 1.0% .0% 1.7%
No medications 46.4% 53.8% 41.4%
Total medications 1.2 .9 1.4
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no difference between two 18–45 year old female control
groups (familial or mothers of children with DD negative
for FXS), premutation carriers or those with FXS in the
lifetime incidence of anxiety disorders (Sobesky et al.
1994). This finding could be due in part to the genetic
testing available at the time of the study, resulting in poor
identification of the premutation range across groups and
smaller sample size of females with FXS (N=21), as well
as the limited number of anxiety disorders (social phobia
and GAD) assessed by the SADS-L. There have been
disparate reports regarding the psychological problems
experienced by females with FXS. However, this study
affirms anxiety is experienced at similar rates as males,
irrespective of an ASD or ID.
Selective mutism (SM) was the third most common
disorder in the study, occurring in 25.3% of the sample.
Although not formally classified as an anxiety disorder, SM
is considered a severe form of social anxiety. DSM-IV
criteria for SM can be summarized as a consistent failure to
speak in specific social situations, despite speaking in other
situations and is not better explained by a communication
disorder or speech abnormalities. Further, social anxiety
and avoidance (as part of social phobia) may be associated
with SM and both diagnoses can be given. In the general
population, prevalence estimates of SM are 0.47%–0.76%
among children (Viana et al. 2009). Hagerman et al. (1999)
documented the case of a 12-year old female with FXS who
met criteria for SM. To our knowledge, there has been no
other specific investigation of SM in FXS. Previous studies
of psychiatric comorbidity in idiopathic autism have
reported rates below the prevalence estimates of the general
population and significantly lower than the rate found in the
present study (de Bruin et al. 2007). Both autism status and
language ability were taken into account before a diagnosis
of SM was given. The vast majority of the sample met
criteria for social anxiety and one-quarter met criteria for
the additional diagnosis of SM. Though many parents of
individuals with FXS and clinicians may observe selective
talking in social situations, the high rate in this sample
warrants replication.
Currently, the treatment of anxiety in FXS relies heavily
on psychotropic medication, among which SSRIs are the
most commonly prescribed (Berry-Kravis and Potanos
2004). Although over 80% of our sample met criteria for
a DSM-IV anxiety disorder, just 27% were using SSRIs at
the time of assessment. Cognitive-behavioral and pharma-
cological interventions are empirically validated for patients
with anxiety disorders in the general population; however
there has been little research on the utility of these methods
in FXS.
There were no significant differences in the rates of
anxiety relative to proband status or ASD, except for a
higher rate of SM among those with an ASD. This suggests
that the high rate of anxiety disorders in FXS reported here
is unlikely to be associated with clinic referral bias, as the
Table 4 Comparison of anxiety disorder prevalence rates among FXS with ID vs. Idiopathic ID, FXS without ID vs. General Population and FXS
vs. Williams Syndrome
ID comparison
a Non-ID comparison
b Genetic syndrome comparison
c
Anxiety type FXS+ID ID
d FXS-ID Gen. Pop.
e FXS WS
f
Any anxiety disorder 87.9%
* 10.5% 76.3%
* 9.8% 82.5%
* 62.1%
Separation anxiety 10.3% 1.9% 13.5%
* 2.3% 11.5% 6.1%
Social phobia 32.8%
* 1.9% 43.2%
* 4.5% 36.5%
* 2.3%
Specific phobia 70.7%
* 6.8% 42.9%
* 1.3% 59.6% 56.1%
Panic Disorder 6.9% N/A 2.9% N/A 5.4% N/A
-Agoraphobia 1.7% 0.2% 0.0% N/A 1.1% N/A
+Agoraphobia 5.2%
* 0.2% 0.0% N/A 3.2% N/A
Agoraphobia 17.9%
* 1.1% 5.6% 1.4% 12.9% N/A
GAD 21.4%
* 0.0% 27.8%
* 3.1% 23.7%
* 7.6%
OCD 26.8%
* 1.5% 19.4% N/A 23.7%
* 1.5%
PTSD 1.7% 0.0% 8.6% N/A 4.3% 1.5%
Selective mutism 27.6% N/A 22.2% N/A 25.3% N/A
aControl for multiple comparisons used, significant differences are p<.0025
bControl for multiple comparisons used, significant differences are p<.00417
cControl for multiple comparisons used, significant differences are p<.00357
dDekker (2003) using DISC-IV-P, N=474,
eSchaffer (1999) using DISC 2.3, N=1,285,
fLeyfer (2009) N=132 using ADIS-IV
* Difference is significant at the corrected (p) value
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research purposes. However, there was a trend towards
more anxiety disorders and higher rates of specific phobia
among those with an ASD. In a comparison of those with
ID and a pervasive developmental disorder (ID+PDD) and
those with ID without PDD (ID-PDD), Dekker and
colleagues did not find an increased likelihood for any
anxiety disorder, except OCD (Dekker and Koot 2003).
Research examining comorbid diagnoses of anxiety and
idiopathic autism have reported higher scores of anxiety and
social worries in autism compared to controls (Gillott et al.
2001). A recent review concluded that anxiety is common in
children and adolescents with autism spectrum disorders
and may be a source of additional comorbidity (White et al.
2009). Other than SM, significant differences in anxiety
related to autism were not found in this sample, confirming
that anxiety is a pervasive problem in FXS.
The relationships found between the ADAMS, a mea-
sure normed and validated in ID and the ADIS, a DSM-IV
based clinical interview, support the use of both measures
in FXS. The relationship between the social anxiety
disorders (social phobia and selective mutism) and the
ADAMS Social Avoidance subscale demonstrate the
specificity of each measure. The General Anxiety subscale
of the ADAMS was significantly correlated with many of
the ADIS subscales, suggesting it is a good measure of
overall anxiety. The lack of significant relationship between
the ADAMS Depression subscale and any of the ADIS
anxiety diagnoses is notable considering the commonly
found overlap in anxiety and depressive symptoms (Clark
and Watson 1991; Brady and Kendall 1992; Stark and
Laurent 2001).
In comparison to idiopathic ID, the general population,
and WS, FXS had significantly higher rates of the majority
of anxiety disorders. WS is another genetic disorder
characterized by ID. The social behavior of FXS and WS
differ: individuals with WS have a tendency for social
engagement, while individuals with FXS are often charac-
terized as socially withdrawn. The fact that FXS and WS
have similar rates of ID and specific phobia but strikingly
different rates of social phobia suggests that these two
syndromes offer a unique opportunity to elucidate neuro-
anatomical and other biological mechanisms underlying
social behavior.
Recently, there has been increased evidence of
potential biological differences specific to FXS that
may be related to anxiety. Research focusing on the
biological bases of anxiety in FXS have found disruption
of limbic-hypothalamic-pituitary-adrenal (L-HPA) axis
activity and dysregulation of sympathetic-parasympathetic
nervoussystemmodulationinbothhumanstudies(Hessletal.
2002, 2006) and animal-models of FXS (Markham et al.
2006; Spencer et al. 2005). Studies of sympathetic nervous
system activity (Miller et al. 1999; Roberts et al. 2001;
Farzin et al. 2009) have demonstrated enhanced reactivity to
sensory stimuli that is inversely correlated with the level of
FMRP (Miller et al. 1999). This hyperarousal may be
associated with the high rates of anxiety observed in FXS.
Further, the increased activity of metabotropic glutamate 5
receptors (mGluR5) and decreased activity of gamma-
aminobutyric acid (GABA) that have been documented in
the animal models of FXS also appear to be related to
anxiety and the use of targeted treatments in FXS may
improve anxiety as has been shown in the mouse model of
FXS (Berry-Kravis et al. 2009; Hagerman et al. 2009).
Finally, recent neuroimaging studies of children and adults
with FXS have implicated limbic structures such as the
amygdala and insula (Hagan et al. 2008;H a a se ta l .2009),
which may mediate these hyper-responsive physiological
systems and play an important role in emotion regulation,
fear reactions and processing social stimuli. Future
research linking these biological mechanisms associated
with anxiety and hyperarousal to appropriate clinical
measures of anxiety will have substantial implications for
treatment and intervention design.
There were several important limitations of the study.
First, although the ADIS has been used in prior studies of
anxiety in ID, it has not been extensively validated for
those with mental impairment. However, the high rates of
anxiety disorders among individuals with FXS who do not
have ID, the significant correlations with specific ADAMS
subscales and the controlled comparison to WS ADIS data
help to substantiate the application of this tool in the FXS
population. Second, interviewers were not always blind to
the FMR1 status of the participants. Third, we only assessed
current disorders and are unable to report the lifetime
incidence of anxiety in this sample. It is possible that some
participants visited our facility seeking assistance with
symptoms that were not salient in the past. Future studies
that balance sample characteristics and recruitment
approaches will validate the findings of this study. Finally,
due to the nature of ID and its associated limitations on
verbal communication and insight, we relied exclusively on
parent report. Many anxiety symptoms are experienced
internally and may not be reflected in external behavior
observed by parents.
This study documents the pervasiveness of clinical anxiety
in FXS. Among those with or without ID or an ASD, male or
female, anxiety is a significant and frequently untreated
problem in FXS. The striking prevalence of anxiety and
previous findings of physiological dysregulation in FXS
necessitates clinical assessment for anxiety disorders in FXS,
along with other standard neuropsychological assessments.
The results uncovered debilitating anxiety symptoms, sug-
gesting a history of diagnostic overshadowing in FXS. With
the advent and increased use of more appropriate measures of
J Neurodevelop Disord (2011) 3:57–67 65psychopathology in ID, the psychological problems in FXS
and other ID populations can be more accurately measured
and treated.
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